Arbutus Biopharma Corp (ABUS) support and resistance · P/E 5.4, rev $6.2M
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This page maps Arbutus Biopharma Corp (ABUS) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ABUS 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ABUS quote page for the session range and the stock page for the full model.
Not investment advice.